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Abstract
Introduction: Mammographic density (MD), as assessed from film screen mammograms, is determined by the
relative content of adipose, connective and epithelial tissue in the female breast. In epidemiological studies, a high
percentage of MD confers a four to six fold risk elevation of developing breast cancer, even after adjustment for
other known breast cancer risk factors. However, the biologic correlates of density are little known.
Methods: Gene expression analysis using whole genome arrays was performed on breast biopsies from 143
women; 79 women with no malignancy (healthy women) and 64 newly diagnosed breast cancer patients, both
included from mammographic centres. Percent MD was determined using a previously validated, computerized
method on scanned mammograms. Significance analysis of microarrays (SAM) was performed to identify genes
influencing MD and a linear regression model was used to assess the independent contribution from different
variables to MD.
Results: SAM-analysis identified 24 genes differentially expressed between samples from breasts with high and low
MD. These genes included three uridine 5′-diphospho-glucuronosyltransferase (UGT) genes and the oestrogen
receptor gene (ESR1). These genes were down-regulated in samples with high MD compared to those with low
MD. The UGT gene products, which are known to inactivate oestrogen metabolites, were also down-regulated in
tumour samples compared to samples from healthy individuals. Several single nucleotide polymorphisms (SNPs) in
the UGT genes associated with the expression of UGT and other genes in their vicinity were identified.
Conclusions: Three UGT enzymes were lower expressed both in breast tissue biopsies from healthy women with
high MD and in biopsies from newly diagnosed breast cancers. The association was strongest amongst young
women and women using hormonal therapy. UGT2B10 predicts MD independently of age, hormone therapy and
parity. Our results indicate that down-regulation of UGT genes in women exposed to female sex hormones is
associated with high MD and might increase the risk of breast cancer.
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Introduction
Breast cancer is a common disease in women. Knowl-
edge about the first steps in tumour initiation is impor-
tant for early detection. However, the exact mechanisms
of tumour initiation are still unknown.
Mammographic density (MD), captured on film screen
mammograms, refers to the content and architectural
structure of the adipose, connective and epithelial tissues
in the female breast [1]. In epidemiological studies, a high
percentage of MD confers a four to six fold elevated risk
of developing breast cancer [1-3] and has been proposed
as a possible surrogate marker for the disease [4]. The
relative risk associated with MDs remains at this magni-
tude even after adjustment for all other known breast can-
cer risk factors. Breasts with high MD have greater tissue
cellularity and more tissue collagen [5]. Still, little is
known as to how MD confers the increased breast cancer
risk. MD is to a large degree an inherited trait, although it
is also influenced by environmental factors, hormone ther-
apy being an evident example [6]. The genetic factors
determining the inheritability are largely unknown.
In order to elucidate how MD increases the risk of
breast cancer; we searched for the biological correlates
to MD. Gene expression analysis on biopsies from
breasts of healthy women with varying degrees of MD
was performed. The gene expression profiles represent
the gene activity of the different cell types in the biopsy,
producing a fingerprint of the breast tissue within the
biopsy of that particular woman.
The breast is an oestrogen-sensitive organ. MD varies
with levels of female hormones, and is reduced after
menopause. The uridine 5′-diphospho-glucuronosyl-
transferase (UGT) genes encode enzymes inactivating
several endogenous and exogenous compounds, includ-
ing sex hormones (Figure 1) [7]. UGT1A1 is known to
be responsible for the glucuronidation of bilirubin, but
is also shown to glucuronidate catechol oestrogens [8,9].
Polymorphisms in this gene have previously been linked
to MD in premenopausal women [10]. UGT2B7 is
known to conjugate oestrone, one of the active oestra-
diol metabolites. This enzyme has previously been found
to be down-regulated in tumour tissue compared with
non-malignant tissue, leading to the conclusion that
UGT expression could lead to the promotion of carcino-
genesis [11] but there are no reports on this gene in
relation to MD in the literature. Less is known about
the other UGT2B genes, although there is extensive
structural homology. We will use the UGT genes as a
term describing three UGT2B genes significantly down-
regulated in our analyses (UGT2B7, UGT2B10 and
UGT2B11). Other UGT genes are specified in the text.
In this study we analysed biopsies from breasts of
healthy women and found genes whose expression is
associated with MD.
Materials and methods
Subjects
The women included in this study had all attended one
of six breast diagnostic centres in Norway that are part
of the governmentally funded National Breast Cancer
Screening Program between 2002 and 2007 [12].
Women were eligible if they did not currently use
Figure 1 UGTs conjugate oestrogen-substrates into biologically inactive oestrogen glucuronides. The figure gives a schematic view with
focus on glucuronidation and not a complete picture of oestradiol metabolism. Androgens are also inactivated by uridine 5’-diphospho-
glucuronosyltransferases (UGTs), but are not included in this illustration.
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anticoagulants, did not have breast implants and were
not currently pregnant or lactating. A total of 186
women were recruited to the study; 120 healthy women
with no malignant disease but some visible density in
the mammograms, referred to here as healthy women,
and 66 women with a newly diagnosed breast cancer. Of
these, quality tested expression data were obtained from
biopsies from 79 healthy women and 64 breast cancer
patients.
The women were either referred to a breast diagnostic
centre for a second look due to some irregularity of the
initial screening mammogram (n = 69) or due to clinical
findings (n = 83). For 34 women the type of referral was
unknown.
The women provided information about height,
weight, parity, hormone therapy use and family history
of breast cancer. Two breast biopsies and three blood
samples were collected from each woman. All women
provided signed informed consent. The study was
approved by the local ethical committee and local
authorities (IRB approval no S-02036).
Core biopsies
Two breast biopsies were obtained from each woman
with a 14 gauge needle, for RNA- and DNA-extraction.
In healthy women, the biopsies were taken from an area
with no visible pathology, but with some MD to ensure
that the biopsies did not contain only fatty tissue, which
yields little RNA. The sampling was guided by ultra-
sound. At one hospital, six of the biopsies from breasts
of healthy women were collected from a benign lesion
(mostly fibroadenomas). For the cancer patients, all
biopsies were taken from the tumour. The tissue was
either fresh-frozen at -80°C or soaked in ethanol and
RNAlater (Ambion, Austin, TX, USA), transported and
subsequently stored at -20°C.
Pathology
The haematoxylin eosinofil sections from the tumours
of the breast cancer patients were evaluated locally and
then re-evaluated by one pathologist (YC). Information
about tumour size, histological grade and type, oestro-
gen and progesterone receptor status, human epidermal
growth factor receptor (HER) 2 status and sentinel node
status was recorded and entered into a database mana-
ged by the Office for Clinical Research at Oslo Univer-
sity Hospital, Radiumhospitalet. Pathology evaluations
were not available for the biopsies from breasts of
healthy women.
RNA-expression analysis
Homogenisation, cell lysis and RNA extraction were
performed using the RNeasy Mini Protocol (Qiagen,
Valencia, CA, USA). RNA quality was controlled by
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA, USA) and concentration was determined
using NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). A total of 40 samples,
mostly from normal breast tissue, were excluded from
further analyses due to a low RNA amount (< 10 ng) or
poor RNA quality. RNA was then amplified and labelled
using the Agilent Low RNA input Fluorescent Linear
Amplification Kit Protocol. Amplified tumour RNA was
labelled by Cy5 (Amersham Biosciences, Little Chalfont,
England, UK) and amplified RNA from Universal
Human total RNA (Stratagene, La Jolla, CA, USA) was
labelled by Cy3 (Amersham Biosciences, Little Chalfont,
England, UK). RNA from the remaining 146 biopsies
was further hybridised on Agilent Human Whole
Genome Oligo Microarrays (G4110A) (Agilent Technol-
ogies, Santa Clara, CA, USA). Three arrays had to be
excluded due to poor quality leaving data from 143 sub-
jects (79 healthy individuals and 64 breast cancer
patients) for further analysis. Of the 79 biopsies from
healthy women, 5 had been obtained from a benign
lesion. By ultrasound and mammography these 5 were
described as fibroadenoma (n = 4) or microcalcification
(n = 1).
RNA-data processing
The microarrays were scanned by an Agilent scanner
(Agilent Technologies, Santa Clara, CA, USA) and
processed in Feature Extraction 9.1.3.1 (Agilent Tech-
nologies, Santa Clara, CA, USA). Locally weighted scat-
terplot smoothing (lowess) was used to normalise the
data. The normalised and log2-transformed data were
stored in the Stanford Microarray Database [13] and
retrieved from the database for further statistical ana-
lyses. Flagged spots were treated as missing values. The
dataset now counted 40,791 probes. Clone IDs with 20%
or more missing values were excluded. Gene filtering
was performed to include only probes with variation
across samples, so that probes with less than three
arrays being at least 1.6 standard deviations from the
mean were excluded. For the 79 healthy women, this
probe filtration resulted in an expression dataset of
9,767 probes and 79 arrays each representing one indivi-
dual. For the breast cancer women, a dataset of 64 arrays
and 10,153 probes were obtained after filtration, and for
both groups combined, a dataset of 143 arrays and
13,699 probes were obtained. Missing values were
imputed in R using the method impute.knn in the
library impute [14].
Genotyping
Blood DNA was extracted by phenol/chloroform extrac-
tion followed by ethanol precipitation (Nuclear Acid
Extractor 340A; Applied Biosystems, Foster City, CA,
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USA) according to standard procedures. UGT genotype
data was retrieved from two sources: genome wide asso-
ciation studies (GWAS) using the Human-1 109K Bead-
Chip (Illumina Inc, San Diego, CA, USA) and candidate
gene-based study using iPlex, Sequenom. For the
GWAS, each sample was subject to whole genome
amplification using Illumina proprietary reagents [15].
The amplified DNA was fragmented and hybridised
according to the protocol. The BeadArray reader
(Illumina Inc, San Diego, CA, USA) with the BeadScan
software (Illumina Inc, San Diego, CA, USA) was used
to image the beadchips. Non-polymorphic probes and
probes with more than 20% missing values and were
excluded and data processed as described previously
[16]. The candidate gene single nucleotide polymorph-
ism (SNP) analyses were performed using the iPLEX
assay in conjunction with the Sequenom MassARRAY
platform. Multiplexing was performed in 384 plates
using 1 ul DNA per well with one well containing up to
29 reactions. The technology is described in detail on
the sequenom web-page [17].
Mammograms
Routine descriptions of mammograms by local radiolo-
gists were collected. Craniocaudal mammograms of both
breasts were digitised using a high-resolution Kodak
Lumisys 85 scanner (Kodak, Rochester, NY, USA). Den-
sity was quantified using the University of Southern
California Madena assessment method [18]. In brief, the
method works as follows: a reader (trained by GU) out-
lines the total area of the breast using a computerised
tool, the software then counts the number of pixels.
This represents the total breast area. MD is assessed (by
GU), first by identifying a region of interest that incor-
porates all dense areas except those representing the
pectoralis muscle and scanning artifacts, and then by
applying a yellow tint to all pixels within the region of
interest shaded at or above a threshold intensity of gray.
The software then counts the tinted pixels, which repre-
sents the area of absolute density. The percent density is
the absolute density area divided by the total breast area
and is the value used for these analyses. Test-retest
reliability was 0.99 for absolute density.
Statistical analysis
Clustering was performed using MatLab (version
R2007b) (The MathWorks Inc., Natick, MA, USA) with
Ward linkage and Euclidean distances. Before clustering,
the data were gene centred, that is, for every probe the
mean expression across all samples was calculated and
was subtracted from the log2-ratios for that gene. This
was performed for visualisation purposes only, clustering
with uncentred data returns the same clusters. Signifi-
cance analysis of microarrays (SAM, Stanford University,
CA, USA) (version 3.02) [19,20] for Excel (Microsoft,
Redmond, WA, USA) was used for analysis of differen-
tially expressed genes between two groups of data. The
data were not gene centred for the SAM analysis. A
total of 500 permutations were used. Quantitative SAM
analysis was used to identify genes differentially
expressed according to MD as a continuous variable.
Statistical significance tests and regression analysis were
performed in R 2.9.0 [21]. To test for difference in the
mean of phenotypic variables (MD, age, body mass
index (BMI)) in different clusters of women, we used
two-sided t-tests (assuming equal variance in the
groups) and analysis of variance (ANOVA) for continu-
ous variables and chi-squared/Fisher’s exact tests for
categorical variables [22]. To investigate the similarities
of distributions of UGT genes between tumour samples
and normal samples with low MD and high MD respec-
tively, Kullback-Leibler distances between normalised
distributions of the histograms of the data were calcu-
lated by use of MatLab (The MathWorks Inc., Natick,
MA, USA). The cancer samples in our study were
grouped into subtypes and assigned a risk group using
the PAM50 gene list published by Parker et al [23].
SNP-analysis was performed using R 2.9.0 [21]. The
association between gene expression and SNPs was
assessed using expression quantitative trait loci (eQTL)
[24]in cis (106 bp on each side of the gene) using the R
package eMap v1.1 [25]. Comparing the akaike informa-
tion criterion for different models predicting MD, the
lower criterion singled out a linear regression model as
the model fitting the distribution of the data best. A lin-
ear regression model was fitted in R 2.9.0 with MD as a
continuous response variable and the following covari-
ates: UGT2B7, two probes for UGT2B10, UGT2B11,
ESR1, age, BMI, current hormone therapy, age at first
birth and parity. Gene expression, age, age at first birth
and BMI were entered into the model as continuous
variables. Stepwise variable selection was performed,
starting with all variables included in the model. For
every step, the variable with the highest P value was
rejected from the model and the model was refitted.
This was repeated until all variables included in the
model had a P value less than 0.05. To correct for
the influence of age, this variable was forced to stay in
the model. A sensitivity analysis was performed exclud-
ing extreme ages (30 years or younger) to check the
robustness of the data. We also fitted linear regression
stratified on age (younger or older than 50 years of age)
and current use of hormone therapy. Gene ontology
analysis was performed by the use of DAVID Bioinfor-
matics Resources 2008 from the National Institute of
Allergy and Infectious Diseases, NIH [26]. Functional
annotation clustering was applied and the following
gene ontology categories were selected: biological
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processes (all), molecular function (all) and the KEGG
pathway database. We included gene ontology terms
with a P value (false discovery rate (FDR)-corrected) of
less than 0.01 containing between 5 and 500 genes.
The normalised, log2-transformed data are available in
Gene Expression Omnibus with accession number
[GEO:GSE18672]. The data are not gene centered or
gene filtered.
Results
Gene expression and mammographic density
To identify genes differentially expressed according to MD
we performed quantitative SAM with MD as a continuous
variable using gene expression data from the normal biop-
sies. Of 9,767 probes, only 25 probes, representing 24
genes, were differentially expressed according to MD, with
reduced expression associated with higher MD (FDR <
25%; Table 1) [see Additional file 1]. Gene ontology analy-
sis revealed no significant terms and we found no pathway
associated with this gene set. The UGT genes and oestro-
gen receptor gene (ESR1) were among the genes signifi-
cantly down-regulated in breasts with high MD. The
percentage of samples with low UGT expression was
higher in tumour samples than in normal samples with
low MD, whereas the percentage was more similar
between tumour samples and normal samples with high
MD [see Figure S1 in Additional file 2]. The function of
UGT-enzymes in oestradiol metabolism is illustrated in
Figure 1. In healthy women, the expression of the different
UGT genes was highly correlated with each other and the
four probes clustered together [see Figures S2 and S3 and
Table S1 in Additional file 2].
MD was lower in women with BMI of 25 or more com-
pared with those with BMI of less than 25 (P = 0.01), but
unrelated to other epidemiological variables. UGT
expression was not significantly associated with age, BMI,
age at first birth or current hormone therapy use in the
healthy women [see Table S2 in Additional file 2].
To dissect the impact of age and hormone therapy
use, we performed SAM analyses to identify differen-
tially expressed genes according to MD, whereas strati-
fying for age and postmenopausal hormone therapy
use. For healthy women younger than 50 years of age,
the UGT genes were not significant at a FDR of 25%.
For healthy women aged 50 years or older, 49 probes
were significantly down-regulated in breasts with MD
of 30% or higher (FDR < 25%). Of these, 17 were over-
lapping with those significantly down-regulated among
healthy women in the unstratified analysis. The UGT
genes were not in this list. We then stratified the
women aged 50 years or older on current hormone
therapy use. When only those currently using hormone
therapy were included in the analysis, UGT2B7 and
UGT2B11 were among the six genes differentially
expressed with an FDR less than 10E-5 and UGT2B28
with FDR less than 25%. For healthy women above 50
years of age and not currently using hormone therapy,
several of the 24 genes were differentially expressed
according to MD with an FDR of less than 25%, but
again the UGT genes were not in this list [see Addi-
tional file 3].
These analyses were confirmed fitting a linear regres-
sion model. Although the other variables were excluded
from the model with insignificant P values, age was kept
in the model to control for the age-effect. After stepwise
variable selection, the only significant variables remain-
ing in the model were UGT2B10 (A_23_P7342)(P =
0.005) and BMI (P = 0.015). Sensitivity analysis exclud-
ing extreme ages (30 years and younger) did not alter
the results (UGT2B10 P = 0.003, BMI P = 0.016) and
indicates the robustness of the results. ESR1 was border-
line significant in both these analyses. These results
were not significantly altered when MD was log2-trans-
formed. For further stratification see Table 2.
Unsupervised hierarchical clustering of the 79 samples
from healthy women showed two main clusters. MD
was not significantly different between these two clus-
ters [see Figure S3 in Additional file 2].
Table 1 Genes differentially expressed according to
mammographic density in non-cancer samples
Gene symbol Agilent ID Cytogenetic band
729641 A_24_P932736 8p21.1
FLJ10404 A_23_P427472 5q35.3
VPS18 A_24_P18802 15q15.1
UGT2B10 A_23_P7342 4q13.2
CABP7 A_24_P177236 22q12.2
CD86 A_24_P131589 3q13.33
UGT2B11 A_23_P212968 4q13.2
580687 A_23_P152570 17p11.2
DIAPH2::RPA4 A_23_P254212 Xq21.33
LMOD1 A_32_P199824 1q32.1
UGT2B10 A_24_P521559 4q13.2
PIK3R5 A_23_P66543 17p13.1
ATG7 A_32_P107994 3p25.2
LRRC2 A_23_P155463 3p21.31
RBL1 A_23_P28733 20q11.23
NPY1R A_23_P69699 4q32.2
810781 A_23_P144244 3q13.33
593535 A_32_P80016 15q26.1
H2AFJ A_23_P204277 12p12.3
666399 A_32_P35668 20p12.3
Transcribed A_24_P640617 2p25.2
Transcribed A_32_P20997 20q13.13
UGT2B7 A_23_P136671 4q13
ESR1 A_23_P309739 6q25.1
SAPS1 A_23_P119448 19q13.42
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In the breast cancer group, MD was significantly asso-
ciated with age and BMI, with higher MD in the
younger women and in those with BMI less than 25.
Both MD and UGT expression tended to be higher in
women with receptor positive tumours, but this was not
significant for any type of receptor. UGT-expression in
tumours was unrelated to age, BMI, age at first birth
and current hormone therapy (data not shown). There
was a higher proportion of oestrogen receptor positive
tumours among the breast cancer patients with high
MD (≥ 30%) compared with low (< 30%) MD (10 of 10
vs 36 of 40, Fisher’s = 0.001). There was no significant
association between tumour subtype and level of MD as
assessed by ANOVA. There was no indication that
degree of MD was associated with the risk of relapse as
assessed by the method of Parker et al [23] [see Figure
S4 of Additional file 2].
Nine probes were differentially expressed according to
MD in cancer samples (FDR < 25%; Table 3). None of
these were overlapping with the 24 genes differentially
Table 2 Linear regression analysis of factors predicting mammographic density in all women and stratified for age
and hormone therapy use
Women in model N Variables Beta value P value
All women 76 UGT2B101) -0.6 0.902
UGT2B7 1.8 0.631
UGT2B11 4.8 0.275
ESR1 -3.8 0.055
UGT2B102) -5.6 0.005
BMI -1.5 0.015
age -0.4 0.074
50 years or older 46 UGT2B11 0.2 0.987
UGT2B101) 1.0 0.946
UGT2B7 3.5 0.486
UGT2B102) -3.7 0.073
BMI -1.4 0.052
ESR1 -6.0 0.016
age -0.9 0.061
50 years or older, currently on hormone therapy 11 UGT2B101) 7.2 0.771
UGT2B11 -5.8 0.695
BMI -2.9 0.103
UGT2B7 6.8 0.418
UGT2B102) -27.0 0.000
ESR1 -8.1 0.011
age -0.9 0.103
50 years or older, never used hormone therapy 28 UGT2B11 -0.7 0.948
UGT2B101) 3.3 0.809
UGT2B7 3.1 0.555
UGT2B102) -1.4 0.607
BMI -0.9 0.348
ESR1 -6.0 0.033
Age -1.5 0.004
Younger than 50 years 30 UGT2B7 0.4 0.950
UGT2B101) -1.2 0.866
ESR1 -0.9 0.835
UGT2B11 8.4 0.225
BMI -1.4 0.216
UGT2B102) -6.2 0.040
Age -0.3 0.610
1) A_24_P521559, 2) A_23_P7342
Factors predicting mammographic density (MD) after stepwise exclusion of non-significant factors are shown. Variables listed in the order of exclusion from the
model. P value from the last equation including the variable is shown. Age is forced to stay in the model. UGT2B10 (A_23_P7342) is a significant, independent
predictor of MD in all analyses with a majority of women under influence of female hormones; women younger than 50 years of age and women currently on
hormone therapy. BMI, body mass index.
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expressed in the samples from the breasts of healthy
women.
Genetic polymorphisms
In order to identify genetic determinants of the expression
of the UGT genes found to be associated with MD, we
performed eQTL analyses of SNPs in these genes as avail-
able from an array based GWAS study and a candidate
gene study. Twenty one SNPs in UGT genes were present
on the 109 K array from Illumina, and 9 SNPs from the
candidate gene analysis. Of these, 5 SNPs were associated
with the expression of UGT genes or other genes in their
vicinity at P = 0.05 [see Additional file 4]. Two of these
SNPs, both located in UGT2B10 (rs1828705, rs1828705),
were significantly associated with gene expression of
another UGT gene (UGT2B7 and UGT2B28).
Discussion
Previously, whole genome expression profiling of normal
breast tissue (all cell types included) has been performed
to a limited extent [27,28]. Yang et al recently per-
formed a study of cancer-free breast tissue obtained
from mastectomies in breast cancer patients with high
and low MD [29]. They identified a list of 73 genes dif-
ferentially expressed between high and low MD samples.
Specifically, this included the down-regulation of several
transforming growth factor (TGF) b-related genes in
samples with high MD. In the present study we analysed
breast biopsies from 79 healthy women and tumours of
64 women with breast cancer. Twenty-four genes were
differentially expressed according to MD in the healthy
samples. In breast tumours, none of these 24 genes were
found differentially expressed according to MD.
Tumour-specific deregulation of a large number of
mRNA transcripts may be expected to overshadow the
MD signature. In addition, the sample size is limited
and the two sample sets (cases and controls) are not
directly comparable with respect to MD [see Figure S5
in Additional file 2].
In our study, three UGT genes (UGT2B11, UGT2B10
and UGT2B7) were differentially expressed according to
MD in the breasts of healthy women. All these three
enzymes had decreased expression in dense breasts. Pre-
vious knowledge links the UGT enzymes to the metabo-
lism of female hormones known to influence the
mammary glands (Figure 1). The over-representation of
UGT genes on the list of significant genes along with a
biological link makes these genes particularly interesting.
In a linear regression model with age as a confounding
factor, BMI and one of two probes for UGT2B10 were
the only significant variables independently predicting
MD, with ESR1 as a borderline significant covariate.
The expression of these three UGT2B genes is highly
correlated to each other and as expected only one probe
remained in the regression model as an independent
predictor of MD. BMI is known to be the strongest and
most consistent epidemiological predictor of MD, and is
expected to remain in the model. It is noteworthy that
one of the UGT genes has an independent predictive
value of a greater significance and magnitude than BMI.
MD is determined by multiple factors. In a study of lim-
ited sample size, we can only expect to identify the
strongest predictors.
UGT2B7 is postulated to protect the breast tissue
from oestrogen metabolites locally [30], and this is con-
sistent with our findings that breasts with higher MD
have reduced expression of this gene. The main metabo-
lites of oestradiol and oestrone (hydroxyl- and methoxy-
oestrogen compounds) bind to the oestrogen receptor,
but with a reduced affinity compared with oestradiol.
UGT2B10 and 11 are not yet reported to be associated
with MD or breast cancer, but UGT2B10 is involved in
the metabolism of tobacco-related nitrosamines [31].
Less is known about UGT2B11. The different UGT2B
genes are located close to each other on chromosome 4
and there is great homology between the genes [see Fig-
ure S6 in Additional file 2]. UGT1A1, previously linked
to MD and breast cancer [32], is not represented on the
microarray used in this study.
We have identified a set of genes differentially
expressed according to MD. Interestingly, the UGT
genes seem, to a greater extent than the other genes, to
be more similarly expressed between tumour samples
and normal samples from breasts with high MD as com-
pared with normal samples from breasts with low MD
[see Table S4 and Figure S7 in Additional file 2]. The
other differentially expressed genes generally express the
same levels in the tumours and in the biopsies from the
healthy women with low MD. We cannot exclude that
the UGT genes confer risk for breast cancer develop-
ment through increasing MD, but further studies would
be needed to investigate this.
Table 3 Genes differentially expressed according to
mammographic density in cancer samples
Agilent ID Gene name FDR (%)
A_32_P171923 730402 0.00
A_32_P480177 TNN 0.00
A_23_P200298 AGL 0.00
A_24_P87036 TMEM16A 0.00
A_23_P312150 EDN2 14.87
A_23_P83388 EPPK1 14.87
A_32_P60065 F2RL2 19.82
A_32_P158272 MRNA 19.82
A_23_P105012 HRASLS2 19.82
FDR, false discovery rate.
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We found the UGT genes to be differentially
expressed in young women and women over 50 years of
age currently on hormone therapy. SAM analysis of MD
in women younger than 50 years did not give any differ-
entially expressed genes with an FDR of less than 25%.
However, several UGT-probes are on the top of the list
of genes down-regulated in samples from breasts with
high MD. The lack of significance could be due to low
sample size (n = 30). As UGT enzymes conjugate oes-
tradiol metabolites, its effect will be greater when there
is an increased level of oestradiol present, whether the
oestradiol is endogenous or exogenous. The linear
regression analysis showed that UGT2B10 was predict-
ing MD independent of age in all women, younger
women and women older than 50 years currently using
hormones. This leads to the hypothesis that decreased
UGT expression in the breast of a woman with
increased levels of female hormones confers an
increased MD and possibly an increased risk of breast
cancer.
The biology in breasts with high and low MD may dif-
fer, partly due to differences in proportion of fatty tis-
sue. Therefore, we looked for differentially expressed
genes in a subset of samples including only samples
from breasts with MD of more than 20%. The fact that
the UGT2B gene family is so strongly represented
among the down-regulated genes (six probes represent-
ing five different UGT2B genes are the only genes differ-
entially expressed with an FDR < 10E-5) indicate that
reduced UGT expression is of greater significance in
breasts with higher MD and lower content of fatty
tissue.
We find that ESR1 is down-regulated in biopsies from
healthy women with high MD compared with those
with low MD. This is not consistent with previous find-
ings [33] and contrary to what one would expect
because ESR1 induces transcription and epithelial
growth and high MD may contain increased amounts of
epithelial cells [34,35]. However, increased levels of oes-
tradiol have been shown to decrease levels of ESR1 in
breast cancer [36], and in normal breast tissue in mon-
keys [37] and in mice [38]. Increased levels of oestradiol
may increase MD. Elevated expression of ESR1 is com-
mon postmenopausally [37] and represents non-prolifer-
ating cells. The association between reduced levels of
ESR1 and high MD may reflect high levels of oestradiol.
We found that ESR1 was only a borderline significant
predictor of MD in models with stepwise exclusion of
covariates. In a model including ESR1 with only age or
age and UGT2B10, ESR1 was significantly predicting
MD. The independent contribution of ESR1 in predict-
ing MD was significant in older women, where the effect
of UGT2B10 was not present. There could be a link
between UGT-expression and ESR1-expression in that
reduced metabolism of oestradiol-metabolites increases
the levels of ESR1-ligands (oestradiol metabolites) and
hence reduces ESR1-levels. The UGT-enzyme activity
may be the cause of the alterations leading to increased
MD by this mechanism. Reduced ESR1 is only border-
line significant in predicting MD and could also be an
intermediate factor.
MD is the result of complex biological processes with-
out any single determining factor. BMI is the single
most important factor found to date, and is also signifi-
cant in this study. Age seems to have its effect mainly
through hormonal influence, except for in postmeno-
pausal women not taking hormones, where age has a
significant, independent effect on MD. MD is not signif-
icantly different between the two main clusters from
unsupervised hierarchical clustering of the samples from
healthy women. MD is hence not related to the main
variation in the normal samples.
The genes whose expression we have found to be
associated with MD do have a fairly high FDR in a SAM
analysis and are not significant in all stratified analyses,
suggesting that they may play a role in only subsets of
individuals and other factors also have a significant con-
tribution. Despite this, in linear regression models
UGT2B10 is an independent predictor of MD along
with BMI.
There is a substantial heritable proportion of MD.
SNPs in UGT genes with influence on the UGT expres-
sion have been described [8,39]. We identified two
UGT-SNPs associated with the expression of other UGT
genes. Due to their homology and co-localisation on the
chromosome, they may share common control loci that
affect the expression of multiple UGT genes. It remains
to be investigated in larger and better powered epide-
miological studies whether any of these SNPs are asso-
ciated to MD per se.
We do not know enough about the variability of
gene expression within normal breasts to know if the
genes relevant for MD are adequately represented by
one biopsy taken from an area with some MD. It is
previously shown that two biopsies from the same
breast tumour, before and after chemotherapy, cluster
together [40]. The tumours may, however, be more
homogenous than normal breast tissue. Variability in
gene expression within each breast will make it diffi-
cult to detect genes with only a minor influence on
MD so that only the strongest factors are identified. In
an unpublished dataset we found no significant differ-
ence between UGT-expression in tumours and normal
adjacent tissue tested by paired t-test [see Table S5 in
Additional file 2]. This is merely an indication that the
expression in one breast might be similar for different
locations in the breast and hence be used to look for
associations with MD.
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In this study, healthy individuals had higher MD than
the breast cancer patients. The women recruited in the
study had been referred to a breast diagnostic centre for
a second look. As high MD confers an increased risk for
breast cancer and mammograms with high MD are
more difficult to interpret, they most likely had a higher
MD. In addition, the inclusion criterion of some visible
MD for biopsy may have influenced the mean MD of
the study population. The two populations are not
directly comparable with respect to MD and related
parameters. This lack of comparability on MD does not
affect the analyses of gene expression among the healthy
women only.
We obtained good quality microarrays from only 79 of
120 healthy women and from 64 of 66 breast cancer
patients. This was due to low mRNA-yield or low
mRNA-quality. The biopsies from healthy women con-
sistently yielded less mRNA than the tumour samples.
There is significantly higher MD in the breasts of
healthy women with successful microarrays than in
those with unsuccessful microarrays (37% vs 29%, P =
0.03). As samples from breasts with low MD are under-
represented in the microarray study, it is more difficult
to identify genes that are differentially expressed
between breast tissue with high and low MD. Despite
these limitations, we have identified differentially
expressed genes. These genes might have a greater sig-
nificance than shown in this study.
Normal breast tissue yields less RNA than tumour tis-
sue. The biopsies in this study were small and in agree-
ment with the pathologist, all tissue from normal
breasts was prioritised for RNA-extraction rather than
histological evaluation. Imprint was not in routine use
in the hospitals where we started this study. In order to
make it possible for the staff to include women in this
study in a busy schedule we had to use procedures
already established. We do therefore not have any infor-
mation about the cell types of the normal biopsies.
Knowledge about the cell types present in the biopsies
would have facilitated the analysis.
The two UGT2B10-probes behave differently in our
dataset. Both probes map to the 3′end of the UGT2B10-
gene by BLAT (98.4% homology for A_23_P7342 and
100% homology for A_24_P521559). The discrepancy in
UGT2B10-expression detected by the two probes may
be due to the fact that they both also share substantial
sequence homology with other, but different UGT2B-
genes.
Conclusions
We have identified a set of genes that are differentially
expressed according to MD in breast samples from
healthy women. Some of these genes are known to
influence MD and breast cancer, such as ESR1 and
UGT2B7. Two less described UGT genes, UGT2B10 and
UGT2B11, are also differentially expressed. The expres-
sion of the three UGT genes is reduced in samples with
high MD and also in tumour samples, but does not vary
between different tumour subtypes or risk groups. The
UGT enzymes are known to conjugate active oestrogen-
metabolites. We show that UGT2B10 expression and
BMI are independent predictors of MD. The influence
of reduced UGT expression was strongest in women
under exposure of female hormones. Two candidate
SNPs are associated with the UGT gene expression in
cis. We hypothesise that reduced expression of UGT
genes in women exposed to female sex hormones,
increase MD and that this may be associated with an
increased risk of breast cancer. Further studies of these
genes are needed to test the hypothesis that the gene
products from these genes protect the breast from the
oestrogen-induced MD and thereby reducing the risk of
breast cancer.
Additional material
Additional file 1: Healthy SAM MD. Significance analysis of microarrays
(SAM) for genes differentially expressed according to mammographic
density (MD).
Additional file 2: Figures and tables. A collection of figures and tables
describing the data set and the uridine 5’-diphospho-
glucuronosyltransferase (UGT) genes. The main text refers to individual
figures and tables in this file.
Additional file 3: Healthy SAM MD stratified. Significance analysis of
microarrays (SAM) for genes differentially expressed according to
mammographic density (MD) stratified on age and use of hormone
therapy.
Additional file 4: eQTL. Expression quantitative trait loci (eQTL) analysis
of single nucleotide polymorphism (SNPs) affecting the expression of
uridine 5’-diphospho-glucuronosyltransferase (UGT) genes in cis.
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